# scPharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/scpharmaceuticals

- Industry: Medical Devices & Equipment
- Headquarters: Burlington, US
- Website: www.scpharma.com
- Total disclosed funding: $63M
- Latest round: Series B (Dec 22, 2016)
- Investors on record: 4

## About

scPharmaceuticals, Inc. is a US-based biopharmaceutical company dedicated to developing innovative cardiorenal healthcare solutions, focusing on its injectable product, FUROSCIX®, to enhance treatment efficiency for patients with heart and kidney conditions.Founded in 2014 and headquartered in Burlington, US, scPharmaceuticals, Inc. specializes in cardiorenal health solutions. The company has raised a total of USD 50.00 mn, with its most recent funding round being a Private Placement/Follow on in November 2017, aimed at supporting product launch and development. The current CEO is John Tucker, alongside Pieter Muntendam.scPharmaceuticals Inc. specializes in the development and commercialization of innovative cardiorenal healthcare solutions, with a primary focus on the commercialization of its flagship product, FUROSCIX®. This injectable formulation of furosemide offers an alternative to traditional intravenous administration for patients with heart failure and chronic kidney disease. FUROSCIX® aims to reduce treatment time significantly, enhancing convenience and effectiveness in medication delivery. The company targets healthcare providers, hospitals, and outpatient facilities in the US, with plans to expand into international markets as regulatory approvals are obtained.scPharmaceuticals reported net revenue of USD 36.33 mn for the year 2024, primarily generated from FUROSCIX® sales. Their revenue model is based on direct sales to healthcare providers and institutions, facilitating B2B interactions within the healthcare ecosystem. The formal launch of FUROSCIX® for an expanded indication showcases their commitment to growing revenue through product diversification.scPharmaceuticals plans to utilize recent funding from its November 2017 IPO, where it raised USD 89.6 mn, to support the launch of FUROSCIX® and the sc2Wear Infusor. They also aim to continue developing their antibiotic pipeline products. The company is focused on expanding its presence in new markets, specifically targeting international regions as regulatory approvals are secured.

## Funding rounds

- Series B, Dec 22, 2016, $47M — OrbiMed Advisors, 5AM Ventures, Lundbeckfond Ventures, Sun Pharmaceutical Industries Limited
- Series A, Mar 26, 2014, $16M — 5AM Ventures, Lundbeckfond Ventures

## Investors

- 5AM Ventures (https://capitalatlas.ai/funds/5am-ventures) — Series A, Series B
- Lundbeckfond Ventures (https://capitalatlas.ai/funds/lundbeckfond-ventures) — Series A, Series B
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series B
- Sun Pharmaceutical Industries Limited — Series B